NCT03735030View on ClinicalTrials.gov

Comparative Bioavailability Study of Human Chorionic Gonadotropin (hCG)-IBSA Versus a Marketed hCG Formulation

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

November 27, 2018

Primary Completion Date

August 2, 2019

Study Completion Date

August 2, 2019

Conditions
Infertility
Interventions
DRUG

Human hCG 10'000 IU

A single dose of 10'000 IU of human hCG will be injected in 24 healthy subject volunteers.

DRUG

Recombinant hCG 6'500 IU

A single dose of 6'500 IU recombinant hCG will be injected in 24 healthy subject volunteers.

Trial Locations (1)

6864

CROSS Research SA, Arzo

Sponsors
All Listed Sponsors
lead

IBSA Institut Biochimique SA

INDUSTRY

NCT03735030 - Comparative Bioavailability Study of Human Chorionic Gonadotropin (hCG)-IBSA Versus a Marketed hCG Formulation | Biotech Hunter | Biotech Hunter